#USA #New York #Pomerantz Law Firm #Larimar Therapeutics #LRMR

Pomerantz Law Firm Investigates Larimar Therapeutics

Pomerantz LLP, a prominent law firm recognized for its expertise in corporate and securities litigation, has recently announced its investigation into potential claims on behalf of investors of Larimar Therapeutics, Inc. (NASDAQ: LRMR), a biopharmaceutical company. This step is aimed at uncovering any securities fraud or unlawful business practices allegedly committed by Larimar or its executives.

Background of Larimar Therapeutics

Founded with a mission to develop innovative therapies for rare diseases, Larimar Therapeutics specializes in the treatment of Friedreich's Ataxia, a rare genetic disorder that affects movement and coordination. One of its leading products under investigation is nomlabofusp, a potential treatment currently undergoing clinical trials. The firm has been in the spotlight recently due to announcements related to these trials and subsequent stock performance.

The Allegations

The investigation was prompted by recent findings released by Larimar. On September 29, 2025, the company shared data from an ongoing long-term open-label study evaluating the safety and efficacy of nomlabofusp. While the company portrayed the results as “positive,” the report disclosed concerning incidents of anaphylaxis, a severe allergic reaction, in several participants. This troubling data led to a significant drop in the company’s stock price, losing approximately 33.66% in value on that very day.

Further compounding concerns, on June 29, 2026, Larimar reported new results from the same trial, indicating that anaphylaxis had now occurred in 10 out of 43 patients. Although the firm continued to claim favorable outcomes from the study, this reassessment of safety signals triggered another 12.57% decline in the stock price, leading to further scrutiny from investors.

Potential Impact on Investors

For investors affected by these significant fluctuations, the Pomerantz Law Firm is advising them to come forward and share their experiences. Those with investments in Larimar Therapeutics during this turbulent time are encouraged to contact the firm to discuss potential inclusion in a class action lawsuit. This could provide them with an avenue to seek compensation for their financial losses potentially linked to the company's disclosures.

The investigation's scope involves determining whether Larimar and its executives knowingly misrepresented information or failed to disclose critical safety concerns regarding nomlabofusp, which may have led investors to make uninformed decisions based on potentially misleading data reports.

Pomerantz Law Firm's History

Pomerantz LLP boasts a long history of representing investors and fighting against corporate misconduct. Established over 85 years ago, the firm has been instrumental in securing numerous multimillion-dollar settlements and judgments for victims of securities fraud and other unlawful corporate behaviors. The ongoing investigation into Larimar Therapeutics continues Pomerantz's mission to uphold the rights of shareholders and promote accountability in the corporate sector.

For more information or to get involved, investors are urged to reach out to Danielle Peyton at Pomerantz LLP, who can be contacted at the provided email address or phone number. This is an essential opportunity for affected investors to ensure their voices are heard during the legal proceedings that may arise from this investigation.

By keeping a close eye on the proceedings surrounding Larimar Therapeutics, the Pomerantz Law Firm aims to shed light on the truth of the company’s conduct and advocate for the justice that investors deserve.